Short interest in Polynovo (ASX:PNV) shares is easing. What does this mean?

Is the future looking brighter for Polynovo's stock?

| More on:
most shorted shares webjet

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The amount of Polynovo Ltd (ASX: PNV) shares in the hands of short sellers has dropped recently.

Over the week ending 13 December, Polynovo shares had a 7.5% short interest.

However, in The Motley Fool Australia's latest weekly short selling breakdown, the company's short interest had dropped to 7.2%.

At the time of writing, the Polynovo share price is $1.51, 0.2% lower than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is up 0.4% this morning.

Let's take a look at what the company's falling short interest might mean for its long-term investors.

What does Polynovo's short interest mean for its shares?

The amount of Polynovo's stock held by short sellers has dipped, and it could spell good news for growth investors.

Short sellers aim to profit from a falling share price. Thus, less short selling activity probably means there's greater confidence in the Polynovo share price among some circles.

Perhaps, the rise in apparent confidence is down to its recent performance.

Over the last 30 days, the company's share price has gained 6.6%, boosted by good news released earlier this month.

Polynovo announced it achieved record sales for July and November on 14 December.

It is also recruiting more sales staff in the United States and its search for a new CEO is progressing well.

Additionally, experts are increasingly bullish on the company's stock.

Macquarie recently upgraded its rating for Polynovo's shares to 'outperform', slapping them with a $2.85 price target. That represents an 88% upside on the company's current share price.

As my Foolish colleague, James Mickleboro, recently reported, the broker believes Polynovo's NovoSorb product will be a major catalyst to its growth.

However, the company still sits among the 10 most shorted shares on the ASX. Potentially, due to the stock's performance through 2021.

Since the start of this year, the Polynovo share price has fallen 61%. It's likely many eyes will be on it in the new year in hopes it can correct its tumble.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »